Company Information
Industry 制造业
Company Introduction 百济神州有限公司是一家全球性、商业阶段的生物科技公司,专注于研究、开发、生产以及商业化创新型药物,主要产品百悦泽((BRUKINSA),BTK抑制剂)、百泽安(抗PD-1单抗)、帕米帕利。公司自主研发产品BRUKINSA(百悦泽)实现了中国原研新药出海的“零突破”,并凭借这一里程碑式的突破于2020年获得由中国健康产业创新平台颁发的“药品创新奇璞奖”。同年,公司凭借自主研发产品百泽安获得上海市张江科学城建设管理办公室颁发的“2019年度张江科学城优秀企业创新成果奖”。此外,公司作为承担单位进行了5项国家级科研项目,并在核心期刊上发表了34篇学术论文。
Main Business 研究、开发、生产以及商业化创新型药物
Legal Representative John V. Oyler
Top Executives
执行董事:John V. Oyler
非执行董事:王晓东
独立非执行董事:易清清,Olivier Brandicourt ,Alessandro Riva,Margaret Dugan,Corazon(Corsee)D. Sanders,Anthony C. Hooper,Michael Goller,Ranjeev Krishana,Shalini Sharp
Top 5 Shareholder
Shareholder name Nature Holding Date
安进H股17.77%30/09/2024
HHLRFund,L.P.及其联属实体H股10.31%30/09/2024
BakerBrothersLifeSciences,L.P.及其联属实体H股10.01%30/09/2024
CapitalResearchandManagementCompany及其联属实体H股7.83%30/09/2024
香港中央结算有限公司流通A股0.62%30/09/2024
Company Secretary --
Solicitors 上海市方达律师事务所
Auditors 致同会计师事务所(特殊普通合伙);安永华明会计师事务所(特殊普通合伙)
Tel No 010-58958058
Fax No 010-85148699
Website www.beigene.cn
Email ir@beigene.com
Company Address
Register: Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, PO Box 1348, Grand Caym
Office: 北京市昌平区中关村生命科学园科学园路30号
Listing Date 15/12/2021
Shares Capital
Shares Capital: 1,381,700,524
Total A Share: 115,055,260
Listed A Share: 115,055,260
Non-tradable A Share: 0
Other Share: 0
Total B Share: 0
Total H Share: 1,266,645,264
EPS(RMB)* ¥ -4.950
DPS(RMB)* --
NBV Per Share(RMB)* ¥ 18.530
Market Capitalization(RMB) 20.287B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.